- Sibila M, et al. Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions. Porc Health Manag. 2020;6:11.
- Hyogen® Product Label. Ceva Animal Health Inc. Cambridge, ON.
- Maes D, et al. Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol. 2008;126(4):297-309.
- Tenk M, Rozsnyay Z, Pálmai N, et al. Potentiation of the Mycoplasma hyopneumoniae vaccine efficacy with a novel adjuvant. (2017) In: Proceedings of the 9th European Symposium of Porcine Health Management, Prague, Czech Republic. Data on file. Ceva Santé Animale.
- Herczeg et al. Onset of immunity after one shot of Hyogen J5® - Mycoplasma hyopneumoniae vaccine in pigs. Proceedings Asian Pig veterinary Society, 2011.
- Palya V, et al. Comparison of the efficacy of Circovac® vaccine with another commercial vaccine in the PCV2d challenge model.
- Lasierra M, et al. Comparison between different commercial Mycoplasma hyopneumoniae vaccines under field conditions.
- Circovac® Product Label. Ceva Animal Health Inc. Cambridge, ON.
- Chevalier M, et al. IPVS Congress 2010. Vancouver, Canada.
- Fraile L, et al. Inactivated PCV2 one shot vaccine applied in 3-week-old piglets: improvement of production parameters and interaction with maternally derived immunity. Vaccine. 2012;30(11):1986-92.
- Seo HW, et al. Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines. Vet J. 2014;200(1):65-70.
Garza L, et al. Effect of sow porcine circovirus type 2 (PCV2) vaccination with Circovac® on piglet antibody titre and viraemia at weaning. Proceedings of 12th European Symposium of Porcine Health Management (ESPHM), April 14th-16th, 2021, Bern, Switzerland.
- Oliver-Ferrando S, et al. Exploratory field study on the effect of Porcine circovirus 2 (PCV2) sow vaccination on serological, virological and reproductive parameters in a PCV2 subclinically infected sow herd. BMC Vet Res. 2018;14(1):130.
- Heissenberger B, et al. Efficacy of vaccination of 3-week-old piglets with Circovac® against porcine circovirus diseases (PCVD). Trials Vaccinol. 2013;2:1-9.
Circovac®: Injectable emulsion made from combining a suspension contained a killed porcine circovirus type 2 (PCV2), and an oily emulsion. Contains 50 mL/100 doses for piglets. Indications: Piglets: for the vaccination of piglets 3 weeks of age or older to reduce viremia, virus in lymphoid tissue and fecal excretion of PCV2
and to aid in the reduction of clinical signs associated with porcine circovirus-associated disease. Efficacy was determined through piglet vaccination-challenge studies. Onset of immunity: 2 weeks post-vaccination. Duration of immunity for reduction of viremia and fecal excretion of virus: at least 14 weeks.
Store at 2-7°C. Do not freeze. Do not expose to heat or direct light.
Hyogen®: Active ingredient: Mycoplasma hyopneumoniae 2940 strain. Adjuvants: Light liquid paraffin, Escherichia coli J5 LPS. Excipient: Thiomersal. Indications: For the active immunization of fattening pigs from 3 weeks of age to reduce the occurrence and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. Onset of immunity: 3 weeks after vaccination. Duration of immunity: 26 weeks after vaccination. Store and transport refrigerated (2°C - 8°C). Do not freeze. Protect from light.